Ferinject® 50 mg ironmL solution for injectioninfusion

Země: Malajsie

Jazyk: angličtina

Zdroj: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Koupit nyní

Aktivní složka:

Ferric Carboxymaltose

Dostupné s:

ZUELLIG PHARMA SDN BHD

INN (Mezinárodní Name):

Ferric Carboxymaltose

Jednotky v balení:

10 ml; 20 ml

Výrobce:

IDT BIOLOGIKA GMBH

Informace pro uživatele

                                Not Applicable
                                
                                Přečtěte si celý dokument
                                
                            

Charakteristika produktu

                                200716_SPC-YV007/YV080/YV013/MR/E30 T UK01-MY
1/10
1.
NAME OF THE MEDICINAL PRODUCT
Ferinject 50 mg iron/mL solution for injection/infusion.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One mL of solution contains 50 mg of iron as ferric carboxymaltose.
Each 10 mL vial contains 500 mg of iron as ferric carboxymaltose.
Each 20 mL vial contains 1,000 mg of iron as ferric carboxymaltose.
Excipient(s) with known effect
One mL of solution contains up to 5.5 mg (0.24 mmol) sodium, see
section 4.4.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection/infusion. Dark brown, non-transparent, aqueous
solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Ferinject is indicated for the treatment of iron deficiency when (see
section 5.1):
–
oral iron preparations are ineffective.
–
oral iron preparations cannot be used.
–
there is a clinical need to deliver iron rapidly.
The diagnosis of iron deficiency must be based on laboratory tests.
[e.g., plasma ferritin levels,
haemoglobin, haematocrit, red cell count, MCV, MCH and transferrin
saturation (TSAT).]
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Monitor carefully patients for signs and symptoms of hypersensitivity
reactions during and following
each administration of Ferinject.
Ferinject should only be administered when staff trained to evaluate
and manage anaphylactic
reactions is immediately available, in an environment where full
resuscitation facilities can be
assured. The patient should be observed for adverse effects for at
least 30 minutes following
each Ferinject administration (see section 4.4).
Posology
The posology of Ferinject follows a stepwise approach: [1]
determination of the individual iron need,
[2]
calculation and administration of the iron dose(s), and [3] post-iron
repletion assessments. These
steps are outlined below:
_Step 1: Determination of the iron need _
The individual iron need for repletion using Ferinject is determined
based on the patient’s body weight
and haemoglobin (Hb) level. Refer to T
                                
                                Přečtěte si celý dokument
                                
                            

Vyhledávejte upozornění související s tímto produktem